Wellington Management Group LLP significantly increased its stake in Charles River Laboratories International, now owning 3,740,768 shares valued at $736.8 million. Other institutional investors, including State Street Corp and Allspring Global Investments, also raised their holdings. Despite these investments, analysts maintain a "Hold" rating on the stock, with a current price target of $185, down from $250. The company reported earnings of $2.59 per share, exceeding expectations, but revenue declined 1.6% year-over-year.